Physician profile
Peter Michael Deane
NPI 1811965098
$1,171.43
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $869 · 2020: $174 · 2021: $128.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $162.20 | 2019 | |
| Becton, Dickinson and Company | $128.00 | 2021 | |
| Alk-Abello, INC | $117.93 | 2020 | |
| Regeneron Pharmaceuticals, INC. | $95.91 | 2019 | |
| Pfizer INC. | $95.06 | 2019 | |
| Glaxosmithkline, LLC. | $84.95 | 2019 | |
| Janssen Biotech, INC. | $57.68 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $52.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $44.45 | 2019-2020 | |
| Genzyme Corporation | $44.22 | 2019 | |
| Shire North American Group INC | $41.25 | 2019 | |
| Genentech USA, INC. | $40.97 | 2019 | |
| Lilly USA, LLC | $40.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.98 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $27.48 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2020 | |
| Abbvie INC. | $21.06 | 2019 | |
| Csl Behring | $19.60 | 2019 | |
| Horizon Therapeutics Plc | $17.53 | 2019 | |
| Fidia Pharma USA INC. | $15.22 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.67 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$1,927.55 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Deane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.